| Name | Title | Contact Details |
|---|---|---|
Carrissa Ayoub |
Vice President Information Security | Profile |
The Federal Reserve Board, commonly known as the Fed, is the central authority of the Federal Reserve System, which serves as the central banking system of the United States. Established in 1913, the Fed aims to create a stable monetary system and address banking panics. Headquartered in Washington, D.C., it oversees 12 regional Federal Reserve Banks, balancing regional insights with national policy. The Fed has five main functions: conducting monetary policy to promote maximum employment and stable prices, ensuring financial system stability, supervising and regulating financial institutions, fostering efficient payment and settlement systems, and promoting consumer protection and community development. It also provides essential services such as payment processing and economic data publications, including the Beige Book and the FRED database. The Fed plays a crucial role in supporting the U.S. economy and serves various stakeholders, including depository institutions, the U.S. government, and foreign official institutions.
RCB Bank Ltd, based in Cyprus, was established in 1995 and is known for enhancing economic ties between Russia and Europe. Originally named Russian Commercial Bank (Cyprus) Limited, it received its banking license from the Central Bank of Cyprus. The bank offers a range of typical commercial banking services, likely including corporate and retail banking, investment services, and international transactions. RCB Bank Ltd has expanded its presence in Cyprus with branches in Limassol and Nicosia. RCB Bank, located in Claremore, Oklahoma, was founded in 1936 and has grown to become one of the largest Oklahoma-owned banks. It provides personal and business banking services, loans, and investment products across over 50 locations in Oklahoma and Kansas. The bank emphasizes building strong relationships with its customers and actively participates in community events.
Our approach consists of four primary factors: 1. Provide a personalized experience with every customer interaction. 2. Offer products with inherent value that address unique customer needs. 3. Locally owned and operated. 4. Loans deployed to assist local businesses and residents. Member FDIC. Equal Housing Lender.
Connected Risk Solutions is a suite of wholesale specialists designed to connect our agency partners with the expertise and products needed to propel new business success and best serve clients with complex risks. We provide insurance information and programs to those who serve the healthcare industry, the professional liability needs of real estate firms, and the ever-growing need for cyber insurance across a wide range of industries. Our team of experts knows what agents expect and have built that knowledge into every part of the process. Highland Risk Services is one of the largest wholesale brokers producing insurance for retail agents who specialize in healthcare facilities. In addition to providing the professional and general liability coverage, we also offer work comp solutions to our agents using one of our premier programs. We are here to make you competitive and successful! If you need a broker that can make deals happen - call Highland Risk today!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.